Bronchitis News and Research

RSS

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

Research shows strong links between COPD and heart function

A common lung condition, COPD (chronic obstructive pulmonary disease) diminishes the heart's ability to pump effectively even when the disease has no or mild symptoms, according to research published in the Jan. 21 issue of the New England Journal of Medicine.

21 Jan 2010

One-legged cycling can improve overall fitness in COPD patients

People with chronic-obstructive pulmonary disease (COPD) often find themselves in a downward spiral when it comes to their health. COPD, which includes chronic bronchitis and emphysema, means that the elasticity of the lungs is destroyed.

21 Jan 2010

Study: Heart's ability to pump effectively is diminished among people with common lung disease

A new study from Columbia University Medical Center researchers, has found that the heart's ability to pump effectively is diminished among people with a common lung disease, even in people with no or mild symptoms.

21 Jan 2010

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

18 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

North Carolina takes historic step for health with the implementation of smoke-free law

North Carolina on January 2 will take an historic step for health when it becomes the first major tobacco-growing state to implement a statewide smoke-free law that includes all restaurants and bars. This new law will protect the right of North Carolinians to breathe clean air.

4 Jan 2010

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

Scientists discover five genetic variants associated with lung disease

Scientists have discovered five genetic variants that are associated with the health of the human lung. The research by an international consortium of 96 scientists from 63 centres in Europe and Australia sheds new light on the molecular basis of lung diseases.

14 Dec 2009

Michigan goes smoke-free

The Michigan Legislature today delivered a historic victory for health and the public's right to breathe clean air by passing legislation to make almost all workplaces, including all restaurants and bars, smoke-free. Gov. Jennifer Granholm has said she will sign the bill, which will make Michigan the 27th state to pass a strong smoke-free law that includes all restaurants and bars.

10 Dec 2009

VERTICAL Phase II trial results for NHL released

The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).

9 Dec 2009

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.

8 Dec 2009

VELCADE based regimens are cost-effective for payers and patients, finds study

Millennium: The Takeda Oncology Company today announced that two studies presented at the 51st American Society of Hematology (ASH) Annual Meeting found that VELCADE based regimens are more cost-effective for payers and reduced out-of-pocket costs for patients than other commonly used multiple myeloma treatments.

7 Dec 2009

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing Prodesse's ProParaflu+(TM) assay, a molecular test that detects and differentiates parainfluenza 1, 2 and 3 viruses, which cause lower respiratory tract infections.

25 Nov 2009

Several new vaccines require booster shots to remain effective during a lifetime: Study

Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease prevention. But do all vaccines boost immunity for the same period of time? And, if not, when are additional 'booster shots' needed to keep immunity strong?

24 Nov 2009

Scientists explore various imaging techniques to gain new insight into lung disease

Chronic obstructive pulmonary disease (COPD), a respiratory disease commonly known as chronic bronchitis or emphysema, is the fourth leading cause of death worldwide. 600 million people live with COPD and while researchers have yet to find any real treatment or cure, Grace Parraga of Robarts Research Institute at The University of Western Ontario in London, Canada, is using various imaging techniques to gain new insight into the disease.

21 Nov 2009

New research studies seek to improve diagnosis and treatment for emphysema and other lung diseases

The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants.

20 Nov 2009

Canadian comedian helps raise awareness about COPD

COPD is no joke to Canadian comedian Mary Walsh. "It's shocking that so few Canadians know about COPD considering it's the fourth leading cause of death in this country," says Mary Walsh, spokesperson for The Canadian Lung Association.

18 Nov 2009

CHANTIX/CHAMPIX raises hope for quitting smoking

New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP).

5 Nov 2009

USC: Heavy traffic corridors responsible for preventable childhood asthma

Heavy traffic corridors in the cities of Long Beach and Riverside are responsible for a significant proportion of preventable childhood asthma, and the true impact of air pollution and ship emissions on the disease has likely been underestimated, according to researchers at the University of Southern California (USC).

5 Nov 2009

Bronchitis News and Research

Further Reading

Research shows strong links between COPD and heart function

One-legged cycling can improve overall fitness in COPD patients

Study: Heart's ability to pump effectively is diminished among people with common lung disease

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

VELCADE sNDA receives FDA approval

North Carolina takes historic step for health with the implementation of smoke-free law

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

Scientists discover five genetic variants associated with lung disease

Michigan goes smoke-free

VERTICAL Phase II trial results for NHL released

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

VELCADE based regimens are cost-effective for payers and patients, finds study

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

Several new vaccines require booster shots to remain effective during a lifetime: Study

Scientists explore various imaging techniques to gain new insight into lung disease

New research studies seek to improve diagnosis and treatment for emphysema and other lung diseases

Canadian comedian helps raise awareness about COPD

CHANTIX/CHAMPIX raises hope for quitting smoking

USC: Heavy traffic corridors responsible for preventable childhood asthma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News